Critical challenges and emerging opportunities in hepatitis C virus research in an era of potent antiviral therapy: Considerations for scientists and funding agencies.
Name:
Publisher version
View Source
Access full-text PDFOpen Access
View Source
Check access options
Check access options
Average rating
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Star rating
Your vote was cast
Thank you for your feedback
Thank you for your feedback
Authors
Bartenschlager, RalfBaumert, Thomas F
Bukh, Jens
Houghton, Michael
Lemon, Stanley M
Lindenbach, Brett D
Lohmann, Volker
Moradpour, Darius
Pietschmann, Thomas
Rice, Charles M
Thimme, Robert
Wakita, Takaji
Issue Date
2018-03-02
Metadata
Show full item recordAbstract
The development and clinical implementation of direct-acting antivirals (DAAs) has revolutionized the treatment of chronic hepatitis C. Infection with any hepatitis C virus (HCV) genotype can now be eliminated in more than 95% of patients with short courses of all-oral, well-tolerated drugs, even in those with advanced liver disease and liver transplant recipients. DAAs have proven so successful that some now consider HCV amenable to eradication, and continued research on the virus of little remaining medical relevance. However, given 400,000 HCV-related deaths annually important challenges remain, including identifying those who are infected, providing access to treatment and reducing its costs. Moreover, HCV infection rarely induces sterilizing immunity, and those who have been cured with DAAs remain at risk for reinfection. Thus, it is very unlikely that global eradication and elimination of the cancer risk associated with HCV infection can be achieved without a vaccine, yet research in that direction receives little attention. Further, over the past two decades HCV research has spearheaded numerous fundamental discoveries in the fields of molecular and cell biology, immunology and microbiology. It will continue to do so, given the unique opportunities afforded by the reagents and knowledge base that have been generated in the development and clinical application of DAAs. Considering these critical challenges and new opportunities, we conclude that funding for HCV research must be sustained.Citation
Virus Res. 2018;248:53-62. doi:10.1016/j.virusres.2018.02.016.Affiliation
TwinCore, Zentrum für experimentelle und klinische Infektionsforchung GmbH, Feodor-Lynen-Str.7, 30625 Hannover, Germany.Publisher
ElsevierJournal
Virus researchPubMed ID
29477639Type
ArticleOther
Language
enEISSN
1872-7492ae974a485f413a2113503eed53cd6c53
10.1016/j.virusres.2018.02.016
Scopus Count
The following license files are associated with this item:
- Creative Commons
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-ShareAlike 4.0 International
Related articles
- Hepatitis C virus cell entry: a target for novel antiviral strategies to address limitations of direct acting antivirals.
- Authors: Colpitts CC, Baumert TF
- Issue date: 2016 Sep
- Addressing the Challenges of Hepatitis C Virus Resistance and Treatment Failure.
- Authors: Colpitts CC, Baumert TF
- Issue date: 2016 Aug 16
- Impact of HCV genotype on treatment regimens and drug resistance: a snapshot in time.
- Authors: Cuypers L, Ceccherini-Silberstein F, Van Laethem K, Li G, Vandamme AM, Rockstroh JK
- Issue date: 2016 Nov
- Future landscape of hepatitis C research - Basic, translational and clinical perspectives.
- Authors: Moradpour D, Grakoui A, Manns MP
- Issue date: 2016 Oct
- Revolutionizing hepatitis C treatment: next-gen direct-acting antivirals.
- Authors: Dobrowolska K, Brzdęk M, Rzymski P, Flisiak R, Pawłowska M, Janczura J, Brzdęk K, Zarębska-Michaluk D
- Issue date: 2024 May